Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF
Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.
Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke
All participants were free of ASCVD and had no history of statin use at the start of the study.
Diabetic cardiomyopathy treatment shows promise in ARISE-HF
James Januzzi Jr., MD, said the treatment's overall impact was neutral, but he and his team saw "a very clear and encouraging signal."
Keto diet ‘does not fulfill the criteria of a healthy diet,’ could be harmful for heart patients
The popular high-fat, low-carb diet is associated with multiple short-term benefits, but they appear to diminish over time.
Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment
AskBio, acquired by Bayer for more than $2 billion in 2020, is enrolling patients for a new clinical trial focused on the therapy's effectiveness in adult patients with non-ischemic cardiomyopathy and heart failure.

Abiomed provides multi-year grant to Boston Children's Hospital Heart Center

Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported its donation of an unrestricted grant in the amount of $375,000 to Boston Children's Hospital Heart Center, a newly dedicated cardiovascular care center founded within Boston Children's Hospital.

October 1, 2013

Amgen and Servier announce product collaboration

Amgen and Servier today announced a new collaboration agreement leveraging each company's commitment to cardiovascular disease.

July 9, 2013

The world's leading heart failure congress: Late breaking clinical trials record number of abstracts

The Heart Failure Congress 2013 promises more science than ever this year, with a record number of abstracts submitted. The congress takes place 25-28 May at the Centro de Congressos de Lisboa in Lisbon, Portugal.

April 30, 2013

Wang to lead Division of Cardiovascular Medicine

Thomas Wang, M.D., has joined Vanderbilt as director of the Division of Cardiovascular Medicine and the physician-in-chief of the Vanderbilt Heart and Vascular Institute.

April 19, 2013

James Fang, M.D., to lead cardiovascular medicine at University of Utah

James Chen-tson Fang, M.D., has been named chief of cardiovascular medicine at the University of Utah School of Medicine and director of the cardiovascular service line at University of Utah Health Care.

April 12, 2013

CardioGuide System enables real-time navigation of left ventricular leads during Medtronic CRT implants

Medtronic, Inc. (NYSE:MDT) today announced market release of the CardioGuide™ Implant System, a novel real-time navigation system for cardiac resynchronization therapy pacemakers and defibrillators (CRT-P and CRT-D), in the United States and Canada. The system helps physicians determine the most appropriate location for left-ventricular lead placement by generating 3-D images of the cardiac veins; enhanced software for the system will be commercially available later this year that also analyzes the motion of select cardiac vessels on the left side of the heart. Clinical studies have shown that appropriate left-ventricular lead placement may improve CRT response in heart failure patients (1,2,3).

April 9, 2013

scPharmaceuticals LLC announces strategic partnership with Sensile Medical to develop novel heart failure treatment aimed to reduce readmission rates

scPharmaceuticals LLC today announced that it has entered into a strategic partnership and product development agreement with Sensile Medical Holding AG of Zug, Switzerland to develop an innovative new therapeutic option for patients with heart failure.  The terms of the agreement were not disclosed.

April 8, 2013

ASE: Biomarkers may predict chemo-related cardiotoxicity

According to research presented during the 21st annual scientific sessions of the American Society of Echocardiography (ASE) in San Diego this week, cardiac troponin plasma concentrations and longitudinal strain can predict the development of cardiotoxicity in patients treated with anthracyclines and trastuzumab chemotherapies.

June 15, 2010

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Heart Failure

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

Diabetic cardiomyopathy treatment shows promise in ARISE-HF

Keto diet ‘does not fulfill the criteria of a healthy diet,’ could be harmful for heart patients

Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment

Around the web